The most effective results of a combined anti-PD-1 and anti-CTLA4 immunotherapy was reported to be a 7-year intracranial progression-free survival in 42% of patients with active asymptomatic melanoma brain metastasis which appeared to keep the tumor under control rather than eliminating it [38]. This evidence concerns the gene CTLA4 and neoplasm.